The ecosystem that powered the translation of OCT from fundamental research to clinical and commercial impact [invited]

Biomedical Optics Express

Volumn 8, Issue 3, 2017, Pages 1638-1664

  Swanson, Eric A ^a,b   Fujimoto, James G ^a  

^a Department of Electrical Engineering and Computer Science   (United States)

^b Acacia Communications Inc   (United States)

Author keywords

(170.3880) medical and biological imaging; (170.4500) optical coherence tomography

Indexed keywords

BIOMEDICAL ENGINEERING; COMMERCE; ECOLOGY; ECONOMIC AND SOCIAL EFFECTS; ECOSYSTEMS; MEDICAL IMAGING; MEDICINE; TOMOGRAPHY;

BIOMEDICAL TECHNOLOGIES; CLINICAL PRACTICES; COMPLEX ECOSYSTEMS; FUNDAMENTAL RESEARCH; GOVERNMENT FUNDING; MEDICAL AND BIOLOGICAL IMAGING; MEDICAL TECHNOLOGIES; PHARMACEUTICAL DEVELOPMENT;

OPTICAL TOMOGRAPHY;

BARRETT ESOPHAGUS; CLINICAL MEDICINE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; ECOSYSTEM; ENTREPRENEURSHIP; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; FUNDING; GUIDE WIRE; HEALTH CARE COST; HUMAN; IMAGE QUALITY; LUMPECTOMY; MEDICAL TECHNOLOGY; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PATIENT CARE; QUALITY OF LIFE; REVIEW; SCANNING LASER OPHTHALMOSCOPY; SENSITIVITY AND SPECIFICITY; TELECOMMUNICATION; TREATMENT RESPONSE;

EID: 85016135546     PISSN: None     EISSN: 21567085     Source Type: Journal    
DOI: 10.1364/BOE.8.001638     Document Type: Review

References (53)

1. D. Huang, E. A. Swanson, C. P. Lin, J. S. Schuman, W. G. Stinson, W. Chang, M. R. Hee, T. Flotte, K. Gregory,C. A. Puliafito, and J. G. Fujimoto, “Optical coherence tomography," Science 254(5035), 1178-1181 (1991).
2. E. A. Swanson, “One Decade and $500M: The Impact of Federal Funding on OCT Parts I & II," BioOpticsWorld (2011).
3. J. G. Fujimoto and E. A. Swanson, “The Development, Commercialization, and Impact of Optical Coherence Tomography," Inves. Ophthalmol. Visual Sci. (2016).
4. E. Swanson, “Beyond Better Clinical Care: OCT’s Economic Impact," BioOptics World (2016).
5. E. A. Swanson and D. Huang, “Ophthalmic OCT Reaches $1 Billion per Year: But Reimbursement ClampdownClouds Future Innovation," Retinal Physician 45, 58-59 (2011).
6. E. A. Swanson, “Estimates of Ophthalmic OCT Market Size and the Dramatic Reduction in ReimbursementPayments," http://www.octnews.org/articles/4176266/estimates-of-ophthalmic-oct-market-size-and-the-dr/,(2012).
7. A. E. Fung, G. A. Lalwani, P. J. Rosenfeld, S. R. Dubovy, S. Michels, W. J. Feuer, C. A. Puliafito, J. L. Davis,H. W. Flynn, Jr., and M. Esquiabro, “An optical coherence tomography-guided, variable dosing regimen withintravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration," Am. J. Ophthalmol. 143(4), 566-583 (2007).
8. G. A. Lalwani, P. J. Rosenfeld, A. E. Fung, S. R. Dubovy, S. Michels, W. Feuer, J. L. Davis, H. W. Flynn, Jr., and M. Esquiabro, “A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study," Am. J. Ophthalmol. 148(1), 43-58 (2009).
9. M. A. Windsor, J. J. Sun, E. A. Swanson, P. J. Rosenfeld, K. Frick, and D. Huang, manuscript under preparation.
10. W. Drexler and J. G. Fujimoto, Optical coherence tomography: technology and applications, 2nd Ed. Springer Science & Business Media (2015).
11. S. Wills, “OSA Centennial Snapshots: OCT and the Flowering of Biopotonics," Opt. Photonics News 27(9), 42 (2016).
12. M. Hourihan and D. Parks, “Guide to the President’s Budget, Research & Development FY2017," American Association for the Advancement of Science (AAAS), September 20th, 2016.
13. C. A. Puliafito, M. R. Hee, J. S. Schuman, and J. G. Fujimoto, Optical Coherence Tomography of Ocular Diseases, Thorofare, NJ: Slack, Inc., (1995).
14. E. A. Swanson, “Some Historical Statistics of USPTO Patents in the Field of Optical Coherence Tomography”, http://www.octnews.org/articles/4099230/some-historical-statistics-of-uspto-patents-in-the/, (2012).
15. N. Tanno, T. Ichimura, and A. Saeki, inventors. “Device for measuring the light wave of a reflected image”, Japanese Patent 6-35946. Issued May 11, 1994.
16. E. A. Swanson, D. Huang, J. G. Fujimoto, C. A. Puliafito, C. P. Lin, and J. S. Schuman, inventors, Massachusetts Institute of Technology, assignee, “Method and apparatus for optical imaging with means for controlling the longitudinal range of the sample”, United States Patent 5,321,501, Filed April 29, 1991, Issued June 14, 1994.
17. E. A. Swanson, D. Huang, J. G. Fujimoto, C. A. Puliafito, C. P. Lin, and J. S. Schuman, inventors, Massachusetts Institute of Technology, assignee, “Method and apparatus for performing optical measurements” United States Patent 5,459,570, Filed March 16th, 1993, Issued October 17, 1995.
18. E. A. Swanson, inventors, Massachusetts Institute of Technology, assignee, “Method and Apparatus for Acquiring Images using a CCD Detector Array and No Transverse Scanner”, US Patent Number 5,465,147, Filed June 2, 1994, Issued November 7, 1995.
19. E. A. Swanson and S. R. Chinn, inventors, Massachusetts Institute of Technology, assignee, “Method and apparatus for performing optical measurement using a rapidly frequency -tuned Laser”, United States Patent 5,956,355, Filed February 7, 1997, Issued September 21, 1999.
20. G. Tearney, S. A. Boppart, B. Bouma, M. E. Brezinski, E. A. Swanson, and J. G. Fujimoto, inventors; Massachusetts Institute of Technology, assignee. “Method and apparatus for performing optical measurements using a fiber optical imaging guidewire, catheter, or endoscope” United States Patent 6,134,003, Filed February 27, 1996, Issued October 17, 2000.
21. S. A. Boppart, G. J. Tearney, B. E. Bouma, M. E. Brezinski, J. G. Fujimoto, and E. A. Swanson, inventors, Massachusetts Institute of Technology, assignee, “Methods and Apparatus for Forward-Directed Optical Scanning Instruments”, US Patent Number 6,485,413, Filed March 6, 1998, Issued November 26, 2002.
22. T. Yamaguchi, M. Terashima, T. Akasaka, T. Hayashi, K. Mizuno, T. Muramatsu, M. Nakamura, S. Nakamura, S. Saito, M. Takano, T. Takayama, J. Yoshikawa, and T. Suzuki, “Safety and Feasibility of an Intravascular Optical Coherence Tomography Image Wire System in the Clinical Setting," Eur. Heart J. 31, 401-415 (2010), doi: 10.1093/eurheartj/ehp433.
23. D. S. Ong and I. K. Jang, “Causes, assessment, and treatment of stent thrombosis--intravascular imaging insights," Nat. Rev. Cardiol. 12(6), 325-336 (2015).
24. F. Prati, E. Regar, G. S. Mintz, E. Arbustini, C. Di Mario, I. K. Jang, T. Akasaka, M. Costa, G. Guagliumi, E. Grube, Y. Ozaki, F. Pinto, and P. W. J. Serruys; Expert’s OCT Review Document, “Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis," Eur. Heart J. 31(4), 401-415 (2010), doi: 10.1093/eurheartj/ehp433.
25. T. Yonetsu, B. E. Bouma, K. Kato, J. G. Fujimoto, and I. K. Jang, “Optical coherence tomography- 15 years in cardiology," Circ. J. 77(8), 1933-1940 (2013).
26. Z. A Ali, A. Maehara, P. Généreux, R. A Shlofmitz, F. Fabbiocchi, T. M. Nazif, G. Guagliumi, P. M. Meraj, F. Alfonso, H. Samady, T. Akasaka, E. B. Carlson, M. A Leesar, M. Matsumura, M. O. Ozan, G. S Mintz, O. Ben-Yehuda, G. W Stone, “Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomized controlled trial," The Lanclet, (2016).
27. H. Bezzera, “Intravascular OCT in PCI”, Part 1 and Part 2, American College of Cardiology, June 2016.
28. G. Mintz, “IVUS in PCI guidance”, American College of Cardiology, June 2016.
29. M. Ulrich, L. Themstrup, N. de Carvalho, M. Manfredi, C. Grana, S. Ciardo, R. Kästle, J. Holmes, R. Whitehead, G. B. Jemec, G. Pellacani, and J. Welzel, “Dynamic Optical Coherence Tomography in Dermatology," Dermatology (Basel) 232(3), 298-311 (2016), doi: 10.1159/000444706.
30. H. M. Cheng and P. Guitera, “Systematic review of optical coherence tomography usage in the diagnosis and management of basal cell carcinoma," Br. J. Dermatol. 173(6), 1371-1380 (2015).
31. M. Ulrich, T. von Braunmuehl, H. Kurzen, T. Dirschka, C. Kellner, E. Sattler, C. Berking, J. Welzel, and U. Reinhold, “The sensitivity and specificity of optical coherence tomography for the assisted diagnosis of nonpigmented basal cell carcinoma: an observational study," Br. J. Dermatol. 173(2), 428-435 (2015).
32. T. Gambichler, V. Jaedicke, and S. Terras, “Optical coherence tomography in dermatology: technical and clinical aspects," Arch. Dermatol. Res. 303(7), 457-473 (2011).
33. A. A. Hussain, L. Themstrup, and G. B. E. Jemec, “Optical coherence tomography in the diagnosis of basal cell carcinoma," Arch. Dermatol. Res. 307(1), 1-10 (2015).
34. O. Markowitz, M. Schwartz, E. Feldman, A. Bienenfeld, A. K. Bieber, J. Ellis, U. Alapati, M. Lebwohl, and D. M. Siegel, “Evaluation of optical coherence tomography as a means of identifying earlier stage basal cell carcinomas while reducing the use of diagnostic biopsy," J. Clin. Aesthet. Dermatol. 8(10), 14-20 (2015).
35. L. Schmitz, U. Reinhold, E. Bierhoff, and T. Dirschka, “Optical coherence tomography: its role in daily dermatological practice," J. Dtsch. Dermatol. Ges. 11(6), 499-507 (2013).
36. “NinePoint Medical Licenses 188 Patents and Patent Applications; Patents Support NinePoint’s Broad-BasedPlatform Technology for Development of in vivo Pathology Devices”, NinePoint Medical Press Release,December 13th, 2010.
37. G. J. Ughi, M. J. Gora, A.-F. Swager, A. Soomro, C. Grant, A. Tiernan, M. Rosenberg, J. S. Sauk, N. S.Nishioka, and G. J. Tearney, “Automated segmentation and characterization of esophageal wall in vivo by tethered capsule optical coherence tomography endomicroscopy," Biomed. Opt. Express 7(2), 409-419 (2016), doi: 10.1364/BOE.7.000409.
38. H.-C. Lee, O. O. Ahsen, K. Liang, Z. Wang, C. Cleveland, L. Booth, B. Potsaid, V. Jayaraman, A. E. Cable, H. Mashimo, R. Langer, G. Traverso, and J. G. Fujimoto, “Circumferential optical coherence tomography angiography imaging of the swine esophagus using a micromotor balloon catheter," Biomed. Opt. Express 7(8),2927-2942 (2016), doi: 10.1364/BOE.7.002927.
39. P. Sharma, T. J. Savides, M. I. Canto, D. A. Corley, G. W. Falk, J. R. Goldblum, K. K. Wang, M. B. Wallace,and H. C. Wolfsen; ASGE Technology and Standards of Practice Committee, “The American Society forGastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) onimaging in Barrett’s Esophagus," Gastrointest. Endosc. 76(2), 252-254 (2012).
40. L. Y. Robles, S. Singh, and P. M. Fisichella, “Emerging enhanced imaging technologies of the esophagus: spectroscopy, confocal laser endomicroscopy, and optical coherence tomography," J. Surg. Res. 195(2), 502-514(2015).
41. S. Coda, P. D. Siersema, G. W. H. Stamp, and A. V. Thillainayagam, “Biophotonic endoscopy: a review ofclinical research techniques for optical imaging and sensing of early gastrointestinal cancer," Endosc Int Open 3(5), E380-E392 (2015).
42. C. L. Leggett, D. K. Chan, and K. K. Wang, “Optical Coherence Tomography: Clinical Applications inGastrointestinal Endoscopy." In Endoscopic Imaging Techniques and Tools, edited by Vani J. A. Konda andIrving Waxman, 115-28. Springer International Publishing, 2016.
43. A. J. Trindade, Michael S. Smith, and D. K. Pleskow, “The new kid on the block for advanced imaging inBarrett’s esophagus: a review of volumetric laser endomicroscopy," Ther. Adv. Gastroenterol. 9(3) 408-416,(2016) doi: 10.1177/1756283X16639003.
44. “NinePoint Medical Announces Substantial Hospital Reimbursement Increase for Procedures Using the NvisionVLE Imaging System with Real-time Targeting”, NinePoint Medical Press Release, November 2015.
45. K. Grieve, L. Palazzo, E. Dalimier, P. Vielh, and M. Fabre, “A feasibility study of full-field optical coherence tomography for rapid evaluation of EUS-guided microbiopsy specimens," Gastrointest. Endosc. 81(2), 342-350(2015), doi: 10.1016/j.gie.2014.06.037.
46. H. Blumen, K. Fitch, and V. Polkus, “Comparison of Treatment Costs for Breast Cancer, by Tumor Stage andType of Service," Am. Health Drug Benefits 9(1), 23-32 (2016).
47. L. E. McCahill, R. M. Single, E. J. Aiello Bowles, H. S. Feigelson, T. A. James, T. Barney, J. M. Engel, and A.A. Onitilo, “Variability in reexcision following breast conservation surgery," JAMA 307(5), 467-475 (2012).
48. M. F. Dillon, A. D. K. Hill, C. M. Quinn, E. W. McDermott, and N. O’Higgins, “A pathologic assessment ofadequate margin status in breast-conserving therapy," Ann. Surg. Oncol. 13(3), 333-339 (2006), doi: 10.1245/ASO.2006.03.098.
49. Breast Cancer Facts & Figures, American Cancer Society, 2015-2016.
50. K. L. Kummerow, L. Du, D. F. Penson, Y. Shyr, and M. A. Hooks, “Nationwide trends in mastectomy for early-stage breast cancer," JAMA Surg. 150(1), 9-16 (2015), doi: 10.1001/jamasurg.2014.2895.
51. L. G. Wilke, T. Czechura, C. Wang, B. Lapin, E. Liederbach, D. P. Winchester, and K. Yao, “Repeat surgery after breast conservation for the treatment of stage 0 to II breast carcinoma: a report from the National CancerData Base, 2004-2010," JAMA Surg. 149(12), 1296-1305 (2014).
52. L. N. Metcalfe, “Beyond the margins: Economic costs and complication rates associated with repeated breast-conserving surgeries," J. Clin. Oncol. 34(15S), 1050 (2016).